Results 191 to 200 of about 3,286,390 (370)

Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer [PDF]

arXiv
First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to therapy. 57% patients are diagnosed in late-stage disease due to the tendency of early-stage NSCLC to be asymptomatic. For patients first diagnosed with metastatic disease the 5-
arxiv  

Alterations of immune response of non-small lung cancer with azacytidine [PDF]

, 2013
Innovative therapies are needed for advanced Non-Small Cell Lung Cancer (NSCLC). We have undertaken a genomics based, hypothesis driving, approach to query an emerging potential that epigenetic therapy may sensitize to immune checkpoint therapy targeting
Baylin, Stephen B, Brahmer, Julie R, Brock, Malcolm V, Carvajal, Richard D, De Meyer, Tim, Du, Zhengzong, Easton, Keith, Easwaran, Hariharan, Jones, Peter A, Juergens, Rosalyn A, Koch, Alexander, Laird, Peter W, Mohammad, Helai P, Pardoll, Drew, Parsana, Princy, Rodgers, Kristen, Rudin, Charles M, Taube, Janis M, Topalian, Suzanne L, Tsai, Salina, Tykodi, Scott S, Van Criekinge, Wim, Vendetti, Frank, Wang, Wei, Weisenberger, Daniel J, Wrangle, John, Yen, Ray-Whay, Zahnow, Cynthia A   +27 more
core   +1 more source

Vertical inhibition of p110α/AKT and N‐cadherin enhances treatment efficacy in PIK3CA‐aberrated ovarian cancer cells

Molecular Oncology, Volume 19, Issue 4, Page 1132-1154, April 2025.
PIK3CA amplification and PIK3CA mutation enhance ovarian tumorigenicity through an activation of AKT, which phosphorylates YAP at Ser127. This Ser127 phosphorylation leads to the retention of YAP in the cytoplasm and triggers RAC1 activity, promoting cell migration. Additionally, AKT activation increases expression of N‐cadherin, which further enhances
Shibo Zhang, Hei Ip Hong, Victor C. Y. Mak, Yuan Zhou, Yiling Lu, Guanglei Zhuang, Lydia W. T. Cheung   +6 more
wiley   +1 more source

Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial

Haematologica, 2019
Rohtesh S. Mehta, Roland Bassett, Amanda Olson, Julianne Chen, Sairah Ahmed, Amin M. Alousi, Paolo Anderlini, Gheath Al-Atrash, Qaiser Bashir, Stefan O. Ciurea, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Jeffrey J. Molldrem, Yago Nieto, Betul Oran, Katayoun Rezvani, Muzaffar H. Qazilbash, Samer A. Srour, Elizabeth J. Shpall, Borje S. Andersson, Richard E. Champlin, Uday R. Popat   +24 more
doaj   +1 more source

A statistical framework for detecting therapy-induced resistance from drug screens [PDF]

arXiv
Resistance to therapy remains a significant challenge in cancer treatment, often due to the presence of a stem-like cell population that drives tumor recurrence post-treatment. Moreover, many anticancer therapies induce plasticity, converting initially drug-sensitive cells to a more resistant state, e.g.
arxiv  

ISEV and ISCT statement on EVs from MSCs and other cells: considerations for potential therapeutic agents to suppress COVID-19 [PDF]

, 2020
International Society for Cell and Gene Therapy, International Society for Extracellular Vesicles   +1 more
core  

Integrative systems‐level analysis reveals a contextual crosstalk between hypoxia and global metabolism in human breast tumors

Molecular Oncology, EarlyView.
Breast tumor samples scored for metabolic deregulation (M1 to M3) were given a hypoxia score (HS). The highest HS occurred in patients with strongest metabolic deregulation (M3), supporting tumor aggressiveness. HS correlated with the highest number of metabolic pathways in M1. This suggests hypoxia to be an early event in metabolic deregulation.
Raefa Abou Khouzam, Salem Chouaib, Mohammad Askandar Iqbal   +2 more
wiley   +1 more source

Article Commentary: First Human Myoblast Transfer Therapy Continues to Show Dystrophin after 6 Years

Cell Transplantation, 1997
Peter K. Law Ph.D., Tena G. Goodwin, Qiuwen Fang, Terry L. Hall, Tom Quinley, George Vastagh, Vijaya Duggirala, Charles Larkin, Jerry Ann Florendo, Lawrence Li, Tunja Jackson, T. J. Yoo, Nancy Chase, Michael Neel, Tim Krahn, Randall Holcomb   +15 more
doaj   +1 more source

Thiamine Therapy in Relation to the Glucose Oxidative Pathway in Human Red Cells

, 1962
Charles E. Shields
openalex   +1 more source

Tissue-type plasminogen activator-primed human iPSC-derived neural progenitor cells promote motor recovery after severe spinal cord injury. [PDF]

, 2019
The goal of stem cell therapy for spinal cord injury (SCI) is to restore motor function without exacerbating pain. Induced pluripotent stem cells (iPSC) may be administered by autologous transplantation, avoiding immunologic challenges.
Brifault, Coralie, Campana, Wendy M, Gonias, Steven L, Jeziorski, Jacob J, Kim, John H, Kwon, HyoJun, Mesci, Pinar, Muotri, Alysson R, Nasamran, Chanond, Ohtori, Seiji, Shiga, Akina, Shiga, Yasuhiro   +11 more
core